請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49391
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭錦樺(Ching-Hua Kuo) | |
dc.contributor.author | Shu-Han Chang | en |
dc.contributor.author | 張淑涵 | zh_TW |
dc.date.accessioned | 2021-06-15T11:26:33Z | - |
dc.date.available | 2021-08-26 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-18 | |
dc.identifier.citation | 1. Covey, T.R., E.D. Lee, and J.D. Henion, High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samples. Analytical Chemistry, 1986. 58(12): p. 2453-2460.
2. Annesley, T.M., Ion Suppression in Mass Spectrometry. Clinical Chemistry, 2003. 49(7): p. 1041-1044. 3. 陳家揚, 液相層析�質譜儀的基質效應與因應之道. 化學, 2007. 65(2): p. 151-155. 4. Jensen, P.K., C.E. Wujcik, M.K. McGuire, and M.A. McGuire, Validation of reliable and selective methods for direct determination of glyphosate and aminomethylphosphonic acid in milk and urine using LC-MS/MS. Journal of Environmental Science and Health, Part B, 2016. 51(4): p. 254-259. 5. Chavez-Eng, C.M., R.W. Lutz, H. Li, D. Goykhman, K.P. Bateman, et al., Quantitation of anacetrapib, stable-isotope labeled-anacetrapib (microdose), and four metabolites in human plasma using liquid chromatography tandem mass spectrometry. Journal of Chromatography B, 2016. 1011: p. 204-214. 6. Stahnke, H., T. Reemtsma, and L. Alder, Compensation of Matrix Effects by Postcolumn Infusion of a Monitor Substance in Multiresidue Analysis with LC−MS/MS. Analytical Chemistry, 2009. 81(6): p. 2185-2192. 7. González, O., M. van Vliet, C.W.N. Damen, F.M. van der Kloet, R.J. Vreeken, et al., Matrix Effect Compensation in Small-Molecule Profiling for an LC–TOF Platform Using Multicomponent Postcolumn Infusion. Analytical Chemistry, 2015. 87(12): p. 5921-5929. 8. Cheng, C. and H.-R. Tsai, Analysis of steroids in yeast-mediated cell culture by on-line solid-phase extraction coupled high-performance liquid chromatography electrospray-ionization/mass spectrometry and novel continuous postcolumn infusion of internal standard technique. Analytica Chimica Acta, 2008. 623(2): p. 168-177. 9. Liao, H.-W., G.-Y. Chen, I.L. Tsai, and C.-H. Kuo, Using a postcolumn-infused internal standard for correcting the matrix effects of urine specimens in liquid chromatography–electrospray ionization mass spectrometry. Journal of Chromatography A, 2014. 1327(0): p. 97-104. 10. Poppe, J.K., CLinical experiences with acetylcysteine as a mucolvtic agent. Chest, 1964. 46(1): p. 66-69. 11. Jones, A.L., Mechanism of Action and Value of N-Acetylcysteine in the Treatment of Early and Late Acetaminophen Poisoning: A Critical Review. Journal of Toxicology: Clinical Toxicology, 1998. 36(4): p. 277-285. 12. Sheikh-Hamad, D., K. Timmins, and Z. Jalali, Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. Journal of the American Society of Nephrology, 1997. 8(10): p. 1640-4. 13. Bagshaw, S.M., F.A. McAlister, B.J. Manns, and W.A. Ghali, Acetylcysteine in the prevention of contrast-induced nephropathy: A case study of the pitfalls in the evolution of evidence. Archives of Internal Medicine, 2006. 166(2): p. 161-166. 14. Chyka, P.A., A.Y. Butler, B.J. Holliman, and M.I. Herman, Utility of Acetylcysteine in Treating Poisonings and Adverse Drug Reactions. Drug Safety, 2012. 22(2): p. 123-148. 15. Kopke, R.D., P.A. Weisskopf, J.L. Boone, R.L. Jackson, D.C. Wester, et al., Reduction of noise-induced hearing loss using L-NAC and salicylate in the chinchilla1. Hearing Research, 2000. 149(1–2): p. 138-146. 16. Feghali, J.G., W. Liu, and T.R. Van De Water, L-N-Acetyl-Cysteine Protection Against Cisplatin-Induced Auditory Neuronal and Hair Cell Toxicity. The Laryngoscope, 2001. 111(7): p. 1147-1155. 17. Rybak, L.P. and C.A. Whitworth, Ototoxicity: therapeutic opportunities. Drug Discovery Today, 2005. 10(19): p. 1313-1321. 18. van den Berg, J.H., J.H. Beijnen, A.J.M. Balm, and J.H.M. Schellens, Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treatment Reviews, 2006. 32(5): p. 390-397. 19. Rybak, L.P., C.A. Whitworth, D. Mukherjea, and V. Ramkumar, Mechanisms of cisplatin-induced ototoxicity and prevention. Hearing Research, 2007. 226(1–2): p. 157-167. 20. Thomas Dickey, D., L.L. Muldoon, D.F. Kraemer, and E.A. Neuwelt, Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hearing Research, 2004. 193(1–2): p. 25-30. 21. Choe, W.-T., N. Chinosornvatana, and K.W. Chang, Prevention of Cisplatin Ototoxicity Using Transtympanic N-Acetylcysteine and Lactate. Otology & Neurotology, 2004. 25(6): p. 910-915. 22. Gabard, B. and H. Mascher, Endogenous plasma N-acetylcysteine and single dose oral bioavailability from two different formulations as determined by a new analytical method. Biopharmaceutics & Drug Disposition, 1991. 12(5): p. 343-353. 23. Ercal, N., S. Oztezcan, T.C. Hammond, R.H. Matthews, and D.R. Spitz, High-performance liquid chromatography assay for N-acetylcysteine in biological samples following derivatization with N-(1-pyrenyl)maleimide. Journal of Chromatography B: Biomedical Sciences and Applications, 1996. 685(2): p. 329-334. 24. Isokawa, M., T. Funatsu, and M. Tsunoda, Fast and simultaneous analysis of biothiols by high-performance liquid chromatography with fluorescence detection under hydrophilic interaction chromatography conditions. Analyst, 2013. 138(13): p. 3802-3808. 25. Bald, E. and S. Sypniewski, Determination of thiol drugs in pharmaceutical formulations as their S-pyridinium derivatives by high-performance liquid chromatography with ultraviolet detection. Fresenius' Journal of Analytical Chemistry, 1997. 358(4): p. 554-555. 26. Kuśmierek, K. and E. Bald, Determination of N-Acetylcysteine and Thioglycolic Acid in Human Urine. Chromatographia, 2007. 67(1): p. 23-29. 27. Hannested, U. and B. Sörbo, Determination of 3-mercaptolactate, mercaptoacetate and N-acetylcysteine in urine by gas chromatography. Clinica Chimica Acta, 1979. 95(2): p. 189-200. 28. Longo, A., M. Di Toro, C. Galimberti, and A. Carenzi, Determination of N-acetylcysteine in human plasma by gas chromatography—mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications, 1991. 562(1–2): p. 639-645. 29. Ourique, A.F., K. Coradini, P.d.S. Chaves, S.C. Garcia, A.R. Pohlmann, et al., A LC-UV method to assay N-acetylcysteine without derivatization: analyses of pharmaceutical products. Analytical Methods, 2013. 5(13): p. 3321-3327. 30. Celma, C., J.A. Allué, J. Pruñonosa, C. Peraire, and R. Obach, Determination of N-acetylcysteine in human plasma by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography A, 2000. 870(1–2): p. 13-22. 31. Lu, C., G. Liu, J. Jia, Y. Gui, Y. Liu, et al., Liquid chromatography tandem mass spectrometry method for determination of N-acetylcysteine in human plasma using an isotope-labeled internal standard. Biomedical Chromatography, 2011. 25(4): p. 427-431. 32. Huang, Y.-Q., G.-D. Ruan, J.-Q. Liu, Q. Gao, and Y.-Q. Feng, Use of isotope differential derivatization for simultaneous determination of thiols and oxidized thiols by liquid chromatography tandem mass spectrometry. Analytical Biochemistry, 2011. 416(2): p. 159-166. 33. Holdiness, M.R., Clinical Pharmacokinetics of N-Acetylcysteine. Clinical Pharmacokinetics, 1991. 20(2): p. 123-134. 34. Hekster, F.M., R.W. Laane, and P. de Voogt, Environmental and toxicity effects of perfluoroalkylated substances. Rev Environ Contam Toxicol, 2003. 179: p. 99-121. 35. Li, J., F. Guo, Y. Wang, J. Liu, Z. Cai, et al., Development of extraction methods for the analysis of perfluorinated compounds in human hair and nail by high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography A, 2012. 1219: p. 54-60. 36. Giesy, J.P., J.E. Naile, J.S. Khim, P.D. Jones, and J.L. Newsted, Aquatic toxicology of perfluorinated chemicals. Rev Environ Contam Toxicol, 2010. 202: p. 1-52. 37. Stockholm Convention. The new POPs under the Stockholm Convention. 2009; Available from: http://chm.pops.int/TheConvention/ThePOPs/TheNewPOPs/tabid/2511/Default.aspx. 38. Lindstrom, A.B., M.J. Strynar, and E.L. Libelo, Polyfluorinated Compounds: Past, Present, and Future. Environmental Science & Technology, 2011. 45(19): p. 7954-7961. 39. Lau, C., K. Anitole, C. Hodes, D. Lai, A. Pfahles-Hutchens, et al., Perfluoroalkyl Acids: A Review of Monitoring and Toxicological Findings. Toxicological Sciences, 2007. 99(2): p. 366-394. 40. Butenhoff, J.L., S.-C. Chang, G.W. Olsen, and P.J. Thomford, Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfonate in Sprague Dawley rats. Toxicology, 2012. 293(1–3): p. 1-15. 41. Elcombe, C.R., B.M. Elcombe, J.R. Foster, S.-C. Chang, D.J. Ehresman, et al., Evaluation of hepatic and thyroid responses in male Sprague Dawley rats for up to eighty-four days following seven days of dietary exposure to potassium perfluorooctanesulfonate. Toxicology, 2012. 293(1–3): p. 30-40. 42. Seacat, A.M., P.J. Thomford, K.J. Hansen, L.A. Clemen, S.R. Eldridge, et al., Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology, 2003. 183(1–3): p. 117-131. 43. Seacat, A.M., P.J. Thomford, K.J. Hansen, G.W. Olsen, M.T. Case, et al., Subchronic Toxicity Studies on Perfluorooctanesulfonate Potassium Salt in Cynomolgus Monkeys. Toxicological Sciences, 2002. 68(1): p. 249-264. 44. Kennedy, G.L., J.L. Butenhoff, G.W. Olsen, J.C. O'Connor, A.M. Seacat, et al., The Toxicology of Perfluorooctanoate. Critical Reviews in Toxicology, 2004. 34(4): p. 351-384. 45. Porter, P.L., Global trends in breast cancer incidence and mortality. Salud Pública de México, 2009. 51: p. s141-s146. 46. Ministry of Health and Welfare (Taiwan). Taiwan Cancer Registry. 2011 [cited 2015 27 Jan]; Available from: http://www.hpa.gov.tw/English/ClassShow.aspx?No=201203070002. 47. Leong, S.P.L., Z.-Z. Shen, T.-J. Liu, G. Agarwal, T. Tajima, et al., Is Breast Cancer the Same Disease in Asian and Western Countries? World Journal of Surgery, 2010. 34(10): p. 2308-2324. 48. Bonefeld-Jorgensen, E.C., M. Long, R. Bossi, P. Ayotte, G. Asmund, et al., Perfluorinated compounds are related to breast cancer risk in greenlandic inuit: A case control study. Environmental Health, 2011. 10: p. 88-88. 49. Kim, H.-Y., S.-K. Kim, D.-M. Kang, Y.-S. Hwang, and J.-E. Oh, The relationships between sixteen perfluorinated compound concentrations in blood serum and food, and other parameters, in the general population of South Korea with proportionate stratified sampling method. Science of The Total Environment, 2014. 470–471: p. 1390-1400. 50. Calafat, A.M., X. Ye, M.J. Silva, Z. Kuklenyik, and L.L. Needham, Human exposure assessment to environmental chemicals using biomonitoring. International Journal of Andrology, 2006. 29(1): p. 166-171. 51. Calafat, A.M., L.L. Needham, Z. Kuklenyik, J.A. Reidy, J.S. Tully, et al., Perfluorinated chemicals in selected residents of the American continent. Chemosphere, 2006. 63(3): p. 490-496. 52. Olsen, G.W., D.C. Mair, W.K. Reagen, M.E. Ellefson, D.J. Ehresman, et al., Preliminary evidence of a decline in perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations in American Red Cross blood donors. Chemosphere, 2007. 68(1): p. 105-111. 53. Olsen, G.W., D.C. Mair, T.R. Church, M.E. Ellefson, W.K. Reagen, et al., Decline in Perfluorooctanesulfonate and Other Polyfluoroalkyl Chemicals in American Red Cross Adult Blood Donors, 2000−2006. Environmental Science & Technology, 2008. 42(13): p. 4989-4995. 54. Olsen, G.W., C.C. Lange, M.E. Ellefson, D.C. Mair, T.R. Church, et al., Temporal Trends of Perfluoroalkyl Concentrations in American Red Cross Adult Blood Donors, 2000–2010. Environmental Science & Technology, 2012. 46(11): p. 6330-6338. 55. Liao, H.-W., G.-Y. Chen, M.-S. Wu, W.-C. Liao, I.L. Tsai, et al., Quantification of endogenous metabolites by the postcolumn infused-internal standard method combined with matrix normalization factor in liquid chromatography–electrospray ionization tandem mass spectrometry. Journal of Chromatography A, 2015. 1375: p. 62-68. 56. Liao, H.W., I.L. Tsai, G.Y. Chen, Y.S. Lu, C.H. Lin, et al., Quantification of target analytes in various biofluids using a postcolumn infused-internal standard method combined with matrix normalization factors in liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr A, 2014. 1358: p. 85-92. 57. Liao, H.W., G.Y. Chen, M.S. Wu, W.C. Liao, I.L. Tsai, et al., Quantification of endogenous metabolites by the postcolumn infused-internal standard method combined with matrix normalization factor in liquid chromatography-electrospray ionization tandem mass spectrometry. Journal of Chromatography A, 2015. 1375: p. 62-68. 58. Lin, C.-H., J.-Y. Liau, Y.-S. Lu, C.-S. Huang, W.-C. Lee, et al., Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia. Cancer Epidemiology Biomarkers & Prevention, 2009. 18(6): p. 1807-1814. 59. Raju, U., D.W. Sepkovic, W.R. Miller, J.M. Dixon, H.L. Bradlow, et al., Estrone and estradiol metabolism in vivo in human breast cysts☆1. Steroids, 2000. 65(12): p. 883-888. 60. Rachoń, D., Endocrine disrupting chemicals (EDCs) and female cancer: Informing the patients. Reviews in Endocrine and Metabolic Disorders, 2015. 16(4): p. 359-364. 61. Xia, J., I.V. Sinelnikov, B. Han, and D.S. Wishart, MetaboAnalyst 3.0—making metabolomics more meaningful. Nucleic Acids Research, 2015. 62. Dong, G.H., K.Y. Tung, C.H. Tsai, M.M. Liu, D. Wang, et al., Serum polyfluoroalkyl concentrations, asthma outcomes, and immunological markers in a case-control study of Taiwanese children. Environ Health Perspect, 2013. 121(4): p. 507-13. 63. Nelson, J.W., E.E. Hatch, and T.F. Webster, Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect, 2010. 118(2): p. 197-202. 64. Fromme, H., S.A. Tittlemier, W. Völkel, M. Wilhelm, and D. Twardella, Perfluorinated compounds – Exposure assessment for the general population in western countries. International Journal of Hygiene and Environmental Health, 2009. 212(3): p. 239-270. 65. Haug, L.S., S. Salihovic, I.E. Jogsten, C. Thomsen, B. van Bavel, et al., Levels in food and beverages and daily intake of perfluorinated compounds in Norway. Chemosphere, 2010. 80(10): p. 1137-1143. 66. Haug, L.S., C. Thomsen, A.L. Brantsæter, H.E. Kvalem, M. Haugen, et al., Diet and particularly seafood are major sources of perfluorinated compounds in humans. Environment International, 2010. 36(7): p. 772-778. 67. Lin, Y.C., W.W. Lai, H.H. Tung, and A.Y. Lin, Occurrence of pharmaceuticals, hormones, and perfluorinated compounds in groundwater in Taiwan. Environ Monit Assess, 2015. 187(5): p. 256. 68. Zhao, Y.G., H.T. Wan, A.Y.S. Law, X. Wei, Y.Q. Huang, et al., Risk assessment for human consumption of perfluorinated compound-contaminated freshwater and marine fish from Hong Kong and Xiamen. Chemosphere, 2011. 85(2): p. 277-283. 69. DeRuiter, J., Carboxylic Acid Structure and Chemistry: Part 2. 70. Rayne, S. and K. Forest, Theoretical studies on the pKa values of perfluoroalkyl carboxylic acids. Journal of Molecular Structure: THEOCHEM, 2010. 949(1–3): p. 60-69. 71. Salihovic, S., A. Kärrman, G. Lindström, P.M. Lind, L. Lind, et al., A rapid method for the determination of perfluoroalkyl substances including structural isomers of perfluorooctane sulfonic acid in human serum using 96-well plates and column-switching ultra-high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography A, 2013. 1305: p. 164-170. 72. Jiang, W., Y. Zhang, L. Yang, X. Chu, and L. Zhu, Perfluoroalkyl acids (PFAAs) with isomer analysis in the commercial PFOS and PFOA products in China. Chemosphere, 2015. 127: p. 180-187. 73. Bonefeld-J?rgensen, E.C., M. Long, S.O. Fredslund, R. Bossi, and J. Olsen, Breast cancer risk after exposure to perfluorinated compounds in Danish women: a case–control study nested in the Danish National Birth Cohort. Cancer Causes & Control, 2014. 25(11): p. 1439-1448. 74. Bonefeld-Jorgensen, E.C., M. Long, R. Bossi, P. Ayotte, G. Asmund, et al., Perfluorinated compounds are related to breast cancer risk in Greenlandic Inuit: a case control study. Environ Health, 2011. 10: p. 88. 75. Henry, N.D. and P.A. Fair, Comparison of in vitro cytotoxicity, estrogenicity and anti-estrogenicity of triclosan, perfluorooctane sulfonate and perfluorooctanoic acid. Journal of Applied Toxicology, 2013. 33(4): p. 265-272. 76. Sonthithai, P., T. Suriyo, A. Thiantanawat, P. Watcharasit, M. Ruchirawat, et al., Perfluorinated chemicals, PFOS and PFOA, enhance the estrogenic effects of 17β-estradiol in T47D human breast cancer cells. Journal of Applied Toxicology, 2016. 36(6): p. 790-801. 77. Lin, C.H., P.Y. Chuang, C.J. Chiang, Y.S. Lu, A.L. Cheng, et al., Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. Oncologist, 2014. 19(6): p. 583-91. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49391 | - |
dc.description.abstract | 中文摘要(一)
N-acetylcysteine常作為黏液溶解劑或祛痰劑,也可作為解毒劑,治療Acetaminophen中毒引起的肝損傷。除此之外,近年來有研究指出N-acetylcysteine可能對於Cisplatin等抗癌藥物引起之耳毒性具有預防或治療效果。 本研究開發一簡單、快速、準確且靈敏之超高壓液相層析串聯式質譜儀(UHPLC-MS/MS)分析方法,並應用於測定天竺鼠內耳淋巴液中N-acetylcysteine藥品濃度。因天竺鼠內耳淋巴液樣品量少,方法建立需考量節省樣品,並同時達到良好的靈敏度,本方法經質譜條件最適化後,樣品處理取5 μL淋巴液樣品,加入含內標準品(N-acetylcysteine-15N)之甲醇溶液萃取,經振搖離心後,收集上清液用氮氣吹乾,再用10%甲醇水溶液回溶。液相層析條件選用Poroshell 120 EC-C18作為分析管柱,進樣體積10 μL,移動相使用0.1%甲酸添加於水與乙腈溶液做梯度分析,可在6分鐘內完成分析,質譜條件採用電灑法正離子搭配MRM模式分析,N-acetylcysteine定量離子對m/z 164→m/z 122、定性離子對m/z 164→m/z 76,可獲得最佳的偵測靈敏度及快速且準確的分析結果。 本方法確效結果顯示分析方法之線性範圍1~1000 ng/mL,準確度85.7~107.8%,同日間精密度RSD介於1.37~2.17%之間,異日間精密度RSD皆小於7.32%,定量極限0.5 ng/mL。本研究將開發方法應用於分析天竺鼠給藥後1至48小時之藥物濃度,經耳內注射2% N-acetylcysteine,內耳淋巴液濃度在給藥後1小時測得Cmax為64.6 ± 1.20 μg/mL。 中文摘要(二) 全氟碳化合物(Perfluoroalkyl compounds, PFCs)是化學合成之氟化碳化合物,廣泛使用在工業及各種生活商品上。其具高度化學穩定性之特性,並可能造成肝臟毒性、免疫毒性、生殖發育及神經毒性等,甚至有致癌的風險。近年來,關於這類化合物對環境及人體健康影響越來越被重視。 本研究開發一準確、經濟且靈敏之超高壓液相層析串聯式質譜儀(UHPLC-MS/MS)分析方法測定人體血漿中11種全氟碳化合物濃度,並使用管柱後灌流內標準品(postcolumn infused-internal standard, PCI-IS)結合基質校正因子(matrix normalization factor, MNF)分析策略,校正基質效應及不同基質間的差異,提高定量準確度。 本研究經樣品萃取溶劑、管柱選擇、移動相條件、質譜參數最佳化後,獲得良好的專一性及回收率,液相層析條件選用ACQUITY UPLC® HSS T3 1.8um, 2.1*100mm作為分析管柱,移動相用2 mM ammonium acetate添加於水與甲醇溶液做梯度分析,質譜條件採用電灑法負離子MRM模式分析,可在8.5分鐘內完成分析。本研究選用[13C7]-perfluoroundecanoic acid作為定量使用之柱後灌流內標準品,確效結果顯示本方法之線性範圍0.5~25 ng/mL,準確度大於83.3%,同日間精密度RSD小於9.47%,異日間精密度RSD小於17.15%。 本研究將開發方法應用於乳癌病人血漿中全氟碳化合物之定量分析,195個臨床血漿檢體包含96位乳癌患者與99位正常女性,比較兩組血漿中PFC濃度,未有顯著差異(p>0.05),依年齡分群,挑選出50歲以下之女性年輕族群,包含57位乳癌病患及52位正常女性,結果顯示,PFOS在乳癌患者較正常女性濃度高,有顯著差異(p=0.020),因此PFOS之毒性有可能與乳癌年輕族群之風險因子相關。 本研究提供一個經濟、準確之全氟碳化合物分析平台,可用於研究全氟碳化合物與相關疾病之風險性。 | zh_TW |
dc.description.abstract | Abstract (Ⅰ)
N-acetylcysteine is often used as a mucolytic agent or expectorant, but also as an antidote for the treatment of liver damage caused by acetaminophen poisoning. Several recent studies have found that N-acetylcysteine may have prophylactic or therapeutic effects against the toxic side effects relating to listening impairment caused by anti -cancer drugs such as cisplatin. This study developed a simple, rapid, accurate and sensitive analytical method using ultra-high pressure liquid chromatography tandem mass spectrometry (UHPLC-MS / MS) for N-acetylcysteine quantification. The method was applied to determine N-acetylcysteine concentration in the inner ear lymphatic fluids of guinea pigs. As the volume of guinea pig inner ear lymphatic fluid is generally small, we needed to establish a method which is able to achieve good sensitivity using small volumes. After optimization of the parameters, the final method uses methanol containing N-acetylcysteine-15N, internal standard, as the extraction solution to extract 5 μL of lymphatic fluids . The extract was dried under nitrogen stream and reconstituted in 10% methanol solution. In terms of the liquid chromatographic conditions, we used a Poroshell 120 EC-C18 column and 10 μL as the injection volume. The mobile phases were composed of 0.1% formic acid in the aqueous phase (water) and organic phase (acetonitrile) flowing in a gradient form. The analysis time could be completed in 6 minutes. In the mass conditions, Multiple Reaction Monitoring (MRM) was used coupled with electrospray positive ionization. The quantitative ion pair used to monitor N-acetylcysteine was m/z 164 to m/z 122, and the qualifier ion pair was m/z 164 to m/z 76. This method is able to achieve good detection sensitivity and fast and accurate results. Validation results showed the linear range of the developed method is between 1 ng/mL and 1000 ng/mL, and the accuracy is in the range of 85.7 to 107.8%. The intra-day precision is in the range of 1.37 to 2.17%, and the inter-day precision is less than 7.32%, expressed as the relative standard deviation. The quantification limit is 0.5 ng/mL. The developed method was applied to quantify N-acetylcysteine concentration within 1 to 48 hours post dose in guinea pig inner ear lymphatic fluid. After intratympanic injection of 2% N-acetylcysteine, the perilymph detected the highest concentration of 64.6 ± 1.20 μg/mL at 1 hour post dose. Abstract (Ⅱ) Perfluoroalkyl compounds (PFCs) are chemically produced chemicals. Iit has thus been widely used on many products. Because of its durable characteristics, it is viewed as a persistent organic pollutant. Its effects on the environment and also on the human body have recently become a hot topic. Current literature has linked PFCs to liver, immune, reproductive, and neural toxicity, and it has also been found to be carcinogenic. This study aims to develop an accurate, economic and sensitive method to measure 11 PFCs in human plasma using UHPLC-MS/MS. The Postcolumn Infused-Internal Standard (PCI-IS) combined with Matrix Normalization Factor (MNF) method was applied to correct matrix effects caused quantification errors and provided the accurate quantification of these PFCs. The extraction solvent, column, mobile phase, gradient and various mass parameters were optimized to establish a method with the best sensitivity and selectivity for the selected PFCs, with the final method being run on a ACQUITY UPLC HSS T3 1.8 µm, 2.1*100 mm column, using mobile phases of either water or methanol, both with 2 mM ammonium acetate, and measured using electrospray ionization on negative mode collected with MRM. This analysis is complete within 8.5 minutes. [13C7]-perfluoroundecanoic acid was selected as the PCI-IS for PFCs quantification. The validation results revealed the developed method exhibited a linear range between 0.5 ng/mL and 25 ng/mL, and accuracies above 83.3% with repeatability RSD within 9.47% and reproducibility RSD within 17.2%. The developed method was applied to measure PFC levels in breast cancer patients. A total of 195 clinical subjects were used to evaluate the correlation between PFC and breast cancer risk, with 96 breast cancer patients and 99 healthy volunteers. The results showed no significant difference (p> 0.05) among the 11 PFC compounds in plasma between the two groups. We further analyzed the data by filtering individuals by age, selecting 57 breast cancer patients and 52 healthy volunteers. In the age filtered cohort, PFOS was found to be statistically significant (p = 0.020) between healthy subjects and breast cancer patients. The concentration of PFOS in breast cancer patients is higher than in healthy subjects. Thus, the toxicity of PFOS may be a possible risk factor associated with breast cancer in the younger age group. This study provides an economic and accurate method for the detection of multi-residue analysis of PFC, and it can be used to other studies to invesstigate the risk of PFCs and related diseases. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T11:26:33Z (GMT). No. of bitstreams: 1 ntu-105-R01423014-1.pdf: 2469212 bytes, checksum: fd19f0233699f19d818020b444050d49 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要(一) iv 中文摘要(二) v Abstract (Ⅰ) vii Abstract (Ⅱ) ix 序論 1 第一部分 2 壹、 前言: 2 一、 藥物簡介 2 二、 分析方法 2 貳、 研究目的 3 參、 材料與方法 4 一、 實驗材料 4 (一)、 藥品與試劑 4 (二)、 儀器 4 二、 實驗方法 5 (一)、 動物實驗 5 (二)、 標準品配製 5 (三)、 樣品前處理 5 (四)、 品質管制溶液 6 (五)、 分析條件 6 (六)、 分析方法確效 7 肆、 結果與討論 9 一、 同位素內標準品之校正 9 二、 層析條件之選擇 9 三、 質譜儀參數之最適化 10 四、 分析方法確效 12 五、 天竺鼠內耳淋巴液之藥物動力學 14 伍、 結論 14 第一部分附圖 15 第一部分附表 18 第二部分 19 壹、 前言: 19 一、 全氟碳化合物之應用及危險性 19 二、 全氟碳化合物和乳癌之關聯性 20 三、 分析全氟碳化合物使用的分析策略 20 四、 管柱後灌流內標準品 (postcolumn infusion-internal standard, PCI-IS)方法 20 貳、 研究目的 21 參、 材料與方法 21 一、 實驗材料 21 (一)、 藥品與試劑 21 (二)、 樣品 22 (三)、 儀器 22 二、 實驗方法 23 (一)、 標準品配製 23 (二)、 樣品前處理 24 (三)、 品質管制溶液 24 (四)、 分析條件 24 (五)、 PCI-IS結合MNF校正基質效應之分析方法 25 (六)、 分析方法確效 26 肆、 結果與討論 28 一、 目標分析物之選擇 28 二、 樣品萃取溶劑之選取 29 三、 質譜儀參數之最適化 29 四、 層析條件之選取 32 五、 管柱後灌流內標準品的選擇 33 六、 PCI-IS結合MNF校正基質效應之前後差異 33 七、 分析方法確效 34 八、 全氟碳化合物於乳癌病患之血中濃度研究 35 伍、 結論 39 第二部分附圖 40 第二部分附表 56 總結 62 參考文獻 63 | |
dc.language.iso | zh-TW | |
dc.title | 使用液相層析質譜儀定量生物檢體中之N-acetylcysteine與Perfluoroalkyl compounds | zh_TW |
dc.title | Quantification of N-acetylcysteine and Perfluoroalkyl compounds in Biological Specimens by Liquid Chromatography - Mass Spectrometry | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林季宏,陳家揚 | |
dc.subject.keyword | 乙?半胱胺酸,全氟碳化合物,管柱後灌流內標準品,液相層析/串聯式質譜儀,乳癌,淋巴液,血漿, | zh_TW |
dc.subject.keyword | N-acetylcysteine,perfluoroalkyl compounds,postcolumn infused-internal standard,liquid chromatography tandem mass spectrometry,breast cancer,perilymph,plasma, | en |
dc.relation.page | 68 | |
dc.identifier.doi | 10.6342/NTU201601279 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 2.41 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。